IMMULITE / IMMULITE 1000 AND IMMULITE 2000 FREE PSA ASSAYS
Siemens Medical Solutions Diagnostics Limited · Decision date May 11, 2007
What did the FDA approve?
FDA approved the IMMULITE / IMMULITE 1000 and IMMULITE 2000 Free PSA assays on May 11, 2007. The devices quantitatively measure free prostate-specific antigen not bound to alpha 1-antichymotrypsin or other binding proteins in human serum, including serum collected in glass, plastic, and gel separator tubes.
The measured free PSA is used with the corresponding total PSA assay to calculate percent free PSA. That ratio is indicated as an aid in discriminating prostate cancer from benign disease in men 50 years or older with total PSA values between 4 and 10 ng/mL and digital rectal exam findings not suspicious of cancer. Prostate biopsy is required for diagnosis.
FDA approval order statement
APPROVAL FOR THE IMMULITE / IMMULITE 1000 AND IMMULITE 2000 FREE PSA ASSAY. THESE DEVICES ARE INDICATED FOR: THE IMMULITE / IMMULITE 1000 FREE PSA ASSAY IS INDICATED FOR IN VITRO DIAGNOSTIC USE WITH THE IMMULITE / IMMULITE 1000 ANALYZER FOR THE QUANTITATIVE MEASUREMENT OF FREE PROSTATE-SPECIFIC ANTIGEN (PSA) NOT BOUND TO ALPHA 1-ANTICHYMOTRYPSIN OR OTHER BINDING PROTEINS (UNCOMPLEXED) IN HUMAN SERUM (INCLUDING SERUM COLLECTED IN SERUM GLASS, SERUM PLASTIC AN SERUM GEL SEPARATOR TUBES). MEASUREMENT OF FREE PSA IS USED IN CONJUNCTION WITH IMMULITE / IMMULITE 1000 TOTAL PSA TO DETERMINE A RATIO OF FREE PSA TO TOTAL PSA (PERCENT FREE PSA). THE PERCENT FREE PSA IS USED AS AN AID IN DISCRIMINATING PROSTATE CANCER FROM BENIGN DISEASE IN MEN 50 YEARS OR OLDER WITH IMMULITE / IMMULITE 1000 TOTAL PSA VALUES BETWEEN 4 AND 10 NG/ML AND DIGITAL RECTAL EXAM (DRE) FINDINGS NOT SUSPICIOUS OF CANCER. PROSTATE BIOPSY IS REQUIRED FOR THE DIAGNOSIS OF PROSTATE CANCER. THE IMMULITE 2000 FREE PSA ASSAY IS INDICATED FOR IN VITRO DIAGNOSTIC USE WITH THE IMMULITE 2000 ANALYZER FOR THE QUANTITATIVE MEASUREMENT OF FREE PROSTATE-SPECIFIC ANTIGEN (PSA) NOT BOUND TO ALPHA 1-ANTICHYMOTRYPSIN OR OTHER BINDING PROTEINS (UNCOMPLEXED) IN HUMAN SERUM (INCLUDING SERUM COLLECTED IN SERUM GLASS, SERUM PLASTIC AN SERUM GEL SEPARATOR TUBES). MEASUREMENT OF FREE PSA IS USED IN CONJUNCTION WITH IMMULITE 2000 TOTAL PSA TO DETERMINE A RATIO OF FREE PSA TO TOTAL PSA (PERCENT FREE PSA). THE PERCENT FREE PSA IS USED AS AN AID IN DISCRIMINATING PROSTATE CANCER FROM BENIGN DISEASE IN MEN 50 YEARS OR OLDER WITH IMMULITE 2000 TOTAL PSA VALUES BETWEEN 4 AND 10 NG/ML AND DIGITAL RECTAL EXAM (DRE) FINDINGS NOT SUSPICIOUS OF CANCER. PROSTATE BIOPSY IS REQUIRED FOR THE DIAGNOSIS OF PROSTATE CANCER.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Immunology
- Decision date
- May 11, 2007
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P060005
- Regulatory pathway
- Premarket approval application
- Product code
- MTG
- Decision code
- APPR
- Decision date
- May 11, 2007
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions.
- Product code
- MTG
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P060005 received
Application receipt date recorded by FDA.
P060005 · FDA decision
APPR
P060005/S027 · Related supplement
IMMULITE Systems Free PSA
Timeline entries are records held by MedtechLedger for P060005. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P060005
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
IMMULITE Systems Free PSAP060005/S027 | Siemens Medical Solutions Diagnostics Limited | PMA supplement | Sep 22, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Siemens Medical Solutions Diagnostics Limited
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Glyn Rhonwy Llanberis, Caernarfon, Gwynedd Ll55, 4EL
Sources and methodology
- Original FDA record: P060005
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records